1-20 of 27
J. Carl Barrett
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA

Jhanelle E. Gray, Myung-Ju Ahn, Geoffrey R. Oxnard, Frances A. Shepherd, Fumio Imamura, Ying Cheng, Isamu Okamoto, Byoung Chul Cho, Meng-Chih Lin, Yi-Long Wu, Margarita Majem, Oliver Gautschi, Michael Boyer, Krishna C. Bulusu, Aleksandra Markovets, J. Carl Barrett, Rachel Hodge, Astrid McKeown, Ryan J. Hartmaier, Juliann Chmielecki, Vassiliki A. Papadimitrakopoulou, Suresh S. Ramalingam
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3340–3351.
https://doi.org/10.1158/1078-0432.CCR-22-3146
Published: 01 September 2023
View article titled, Early Clearance of Plasma <em>Epidermal Growth Factor Receptor</em> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA
Open the PDF for Early Clearance of Plasma <em>Epidermal Growth Factor Receptor</em> Mutations as a Predictor of Outcome on Osimertinib in Advanced Non–Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA in another window
Includes: Supplementary data
Journal Articles

Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound

Kim N. Chi, Alan Barnicle, Caroline Sibilla, Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann de Bono, Joaquin Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 81–91.
https://doi.org/10.1158/1078-0432.CCR-22-0931
Published: 04 January 2023
View article titled, Detection of <em>BRCA1</em>, <em>BRCA2</em>, and <em>ATM</em> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound
Open the PDF for Detection of <em>BRCA1</em>, <em>BRCA2</em>, and <em>ATM</em> Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound in another window
Includes: Supplementary data
Journal Articles

Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance

Violeta Serra, Anderson T. Wang, Marta Castroviejo-Bermejo, Urszula M. Polanska, Marta Palafox, Andrea Herencia-Ropero, Gemma N. Jones, Zhongwu Lai, Joshua Armenia, Filippos Michopoulos, Alba Llop-Guevara, Rachel Brough, Aditi Gulati, Stephen J. Pettitt, Krishna C. Bulusu, Jenni Nikkilä, Zena Wilson, Adina Hughes, Paul W.G. Wijnhoven, Ambar Ahmed, Alejandra Bruna, Albert Gris-Oliver, Marta Guzman, Olga Rodríguez, Judit Grueso, Joaquin Arribas, Javier Cortés, Cristina Saura, Alan Lau, Susan Critchlow, Brian Dougherty, Carlos Caldas, Gordon B. Mills, J. Carl Barrett, Josep V. Forment, Elaine Cadogan, Christopher J. Lord, Cristina Cruz, Judith Balmaña, Mark J. O'Connor
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4536–4550.
https://doi.org/10.1158/1078-0432.CCR-22-0568
Published: 14 October 2022
View article titled, Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance
Open the PDF for Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance in another window
Includes: Supplementary data
Journal Articles

Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification

Robert L. Hollis, Alison M. Meynert, Caroline O. Michie, Tzyvia Rye, Michael Churchman, Amelia Hallas-Potts, Ian Croy, W. Glenn McCluggage, Alistair R.W. Williams, Clare Bartos, Yasushi Iida, Aikou Okamoto, Brian Dougherty, J. Carl Barrett, Ruth March, Athena Matakidou, Patricia Roxburgh, Colin A. Semple, D. Paul Harkin, Richard Kennedy, C. Simon Herrington, Charlie Gourley
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (16): 3546–3556.
https://doi.org/10.1158/1078-0432.CCR-22-0368
Published: 15 August 2022
View article titled, Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification
Open the PDF for Multiomic Characterization of High-Grade Serous Ovarian Carcinoma Enables High-Resolution Patient Stratification in another window
Includes: Supplementary data
Journal Articles

Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

Ailith Ewing, Alison Meynert, Michael Churchman, Graeme R. Grimes, Robert L. Hollis, C. Simon Herrington, Tzyvia Rye, Clare Bartos, Ian Croy, Michelle Ferguson, Mairi Lennie, Trevor McGoldrick, Neil McPhail, Nadeem Siddiqui, Suzanne Dowson, Rosalind Glasspool, Melanie Mackean, Fiona Nussey, Brian McDade, Darren Ennis, Lynn McMahon, Athena Matakidou, Brian Dougherty, Ruth March, J. Carl Barrett, Iain A. McNeish, for the Scottish Genomes Partnership, Andrew V. Biankin, Patricia Roxburgh, Charlie Gourley, Colin A. Semple
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (11): 3201–3214.
https://doi.org/10.1158/1078-0432.CCR-20-4068
Published: 01 June 2021
View article titled, Structural Variants at the <em>BRCA1/2</em> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Open the PDF for Structural Variants at the <em>BRCA1/2</em> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma in another window
Includes: Supplementary data
Journal Articles

STAT3 Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1

Theresa A. Proia, Maneesh Singh, Richard Woessner, Larissa Carnevalli, Gayathri Bommakanti, Lukasz Magiera, Srimathi Srinivasan, Shaun Grosskurth, Mike Collins, Chris Womack, Matthew Griffin, Minwei Ye, Susan Cantin, Deanna Russell, Mingchao Xie, Adina Hughes, Nanhua Deng, Deanna A. Mele, Stephen Fawell, Simon Barry, Corinne Reimer, J. Carl Barrett, Patricia McCoon
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (23): 6335–6349.
https://doi.org/10.1158/1078-0432.CCR-20-1066
Published: 01 December 2020
View article titled, <em>STAT3</em> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1
Open the PDF for <em>STAT3</em> Antisense Oligonucleotide Remodels the Suppressive Tumor Microenvironment to Enhance Immune Activation in Combination with Anti–PD-L1 in another window
Includes: Supplementary data
Journal Articles

Abstract A63: Examination of ctDNA false positive variants reported from commercial vendors by ultrasensitive orthogonal testing

Daniel Stetson, Ambar Ahmed, Barrett Nuttall, Tristan Lubinski, J. Carl Barrett, Brian Dougherty
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11_Supplement): A63.
https://doi.org/10.1158/1557-3265.LiqBiop20-A63
Published: 01 June 2020
View article titled, Abstract A63: Examination of ctDNA false positive variants reported from commercial vendors by ultrasensitive orthogonal testing
Journal Articles

Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response

Ben Sidders, Pei Zhang, Kelly Goodwin, Greg O'Connor, Deanna L. Russell, Alexandra Borodovsky, Joshua Armenia, Robert McEwen, Bolan Linghu, Johanna C. Bendell, Todd M. Bauer, Manish R. Patel, Gerald S. Falchook, Melinda Merchant, Gayle Pouliot, J. Carl Barrett, Jonathan R. Dry, Rich Woessner, Kris Sachsenmeier
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (9): 2176–2187.
https://doi.org/10.1158/1078-0432.CCR-19-2183
Published: 01 May 2020
View article titled, Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response
Open the PDF for Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response in another window
Includes: Supplementary data
Journal Articles

The Immunoscore: Colon Cancer and Beyond

Helen K. Angell, Daniela Bruni, J. Carl Barrett, Ronald Herbst, Jérôme Galon
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (2): 332–339.
https://doi.org/10.1158/1078-0432.CCR-18-1851
Published: 15 January 2020
View article titled, The Immunoscore: Colon Cancer and Beyond
Open the PDF for The Immunoscore: Colon Cancer and Beyond in another window
Journal Articles

Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial

Costanza Paoletti, Gaia Schiavon, Emily M. Dolce, Elizabeth P. Darga, T. Hedley Carr, Joseph Geradts, Matthias Hoch, Teresa Klinowska, Justin Lindemann, Gayle Marshall, Shethah Morgan, Parul Patel, Vicky Rowlands, Nitharsan Sathiyayogan, Kimberly Aung, Erika Hamilton, Manish Patel, Anne Armstrong, Komal Jhaveri, Seock-Ah Im, Nadia Iqbal, Fouziah Butt, Caroline Dive, Elizabeth A. Harrington, J. Carl Barrett, Richard Baird, Daniel F. Hayes
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (23): 5860–5872.
https://doi.org/10.1158/1078-0432.CCR-18-1569
Published: 03 December 2018
View article titled, Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial
Open the PDF for Circulating Biomarkers and Resistance to Endocrine Therapy in Metastatic Breast Cancers: Correlative Results from AZD9496 Oral SERD Phase I Trial in another window
Includes: Supplementary data
Journal Articles

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers

Udai Banerji, Emma J. Dean, J. Alejandro Pérez-Fidalgo, Gerald Batist, Philippe L. Bedard, Benoit You, Shannon N. Westin, Peter Kabos, Michelle D. Garrett, Mathew Tall, Helen Ambrose, J. Carl Barrett, T. Hedley Carr, S.Y. Amy Cheung, Claire Corcoran, Marie Cullberg, Barry R. Davies, Elza C. de Bruin, Paul Elvin, Andrew Foxley, Peter Lawrence, Justin P.O. Lindemann, Rhiannon Maudsley, Martin Pass, Vicky Rowlands, Paul Rugman, Gaia Schiavon, James Yates, Jan H.M. Schellens
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2018) 24 (9): 2050–2059.
https://doi.org/10.1158/1078-0432.CCR-17-2260
Published: 30 April 2018
View article titled, A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <em>PIK3CA</em>-Mutated Breast and Gynecologic Cancers
Open the PDF for A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <em>PIK3CA</em>-Mutated Breast and Gynecologic Cancers in another window
Includes: Supplementary data
Journal Articles

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization

Stephanie Lheureux, Zhongwu Lai, Brian A. Dougherty, Sarah Runswick, Darren R. Hodgson, Kirsten M. Timms, Jerry S. Lanchbury, Stan Kaye, Charlie Gourley, David Bowtell, Elise C. Kohn, Claire Scott, Ursula Matulonis, Tony Panzarella, Katherine Karakasis, Julia V. Burnier, C. Blake Gilks, Mark J. O'Connor, Jane D. Robertson, Jonathan Ledermann, J. Carl Barrett, Tony W. Ho, Amit M. Oza
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4086–4094.
https://doi.org/10.1158/1078-0432.CCR-16-2615
Published: 01 August 2017
View article titled, Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Open the PDF for Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization in another window
Includes: Supplementary data
Journal Articles

Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors

Roz Brant, Alan Sharpe, Tom Liptrot, Jonathan R. Dry, Elizabeth A. Harrington, J. Carl Barrett, Nicky Whalley, Christopher Womack, Paul Smith, Darren R. Hodgson
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (6): 1471–1480.
https://doi.org/10.1158/1078-0432.CCR-16-0021
Published: 14 March 2017
View article titled, Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors
Open the PDF for Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors in another window
Includes: Supplementary data
Journal Articles

Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors

Tammie C. Yeh, Greg O'Connor, Philip Petteruti, Austin Dulak, Maureen Hattersley, J. Carl Barrett, Huawei Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (4): 1025–1035.
https://doi.org/10.1158/1078-0432.CCR-16-1658
Published: 14 February 2017
View article titled, Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors
Open the PDF for Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors in another window
Includes: Supplementary data
Journal Articles

Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System

Margaret H. Veldman-Jones, Zhongwu Lai, Mark Wappett, Chris G. Harbron, J. Carl Barrett, Elizabeth A. Harrington, Kenneth S. Thress
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (10): 2367–2378.
https://doi.org/10.1158/1078-0432.CCR-14-0357
Published: 14 May 2015
View article titled, Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System
Open the PDF for Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System in another window
Includes: Supplementary data
Journal Articles

PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

Jeanette Dupont Jensen, Anne-Vibeke Laenkholm, Ann Knoop, Marianne Ewertz, Raj Bandaru, Weihua Liu, Wolfgang Hackl, J. Carl Barrett, Humphrey Gardner
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 667–677.
https://doi.org/10.1158/1078-0432.CCR-10-1133
Published: 15 February 2011
View article titled, <em>PIK3CA</em> Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer
Open the PDF for <em>PIK3CA</em> Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models

Lyuba Varticovski, Melinda G. Hollingshead, Ana I. Robles, Xiaolin Wu, James Cherry, David J. Munroe, Luanne Lukes, Miriam R. Anver, John P. Carter, Suzanne D. Borgel, Howard Stotler, Carrie A. Bonomi, Nomelí P. Nunez, Stephen D. Hursting, Wenhui Qiao, Chuxia X. Deng, Jeff E. Green, Kent W. Hunter, Glenn Merlino, Patricia S. Steeg, Lalage M. Wakefield, J. Carl Barrett
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2168–2177.
https://doi.org/10.1158/1078-0432.CCR-06-0918
Published: 02 April 2007
View article titled, Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models
Open the PDF for Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models in another window
Includes: Supplementary data
Journal Articles

Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of BORIS Expression

John Ian Risinger, Gadisetti V.R. Chandramouli, G. Larry Maxwell, Mary Custer, Svetlana Pack, Dmitri Loukinov, Olga Aprelikova, Tracy Litzi, David S. Schrump, Susan K. Murphy, Andrew Berchuck, Victor Lobanenkov, J. Carl Barrett
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (6): 1713–1719.
https://doi.org/10.1158/1078-0432.CCR-05-2569
Published: 15 March 2007
View article titled, Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of <em>BORIS</em> Expression
Open the PDF for Global Expression Analysis of Cancer/Testis Genes in Uterine Cancers Reveals a High Incidence of <em>BORIS</em> Expression in another window
Includes: Supplementary data
Journal Articles

Prediction of Lymph Node Metastasis in Patients with Endometrioid Endometrial Cancer Using Expression Microarray

Michael A. Bidus, John I. Risinger, Gadisetti V.R. Chandramouli, Lou A. Dainty, Tracy J. Litzi, Andrew Berchuck, J. Carl Barrett, G. Larry Maxwell
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (1): 83–88.
https://doi.org/10.1158/1078-0432.CCR-05-0835
Published: 05 January 2006
View article titled, Prediction of Lymph Node Metastasis in Patients with Endometrioid Endometrial Cancer Using Expression Microarray
Open the PDF for Prediction of Lymph Node Metastasis in Patients with Endometrioid Endometrial Cancer Using Expression Microarray in another window
Includes: Supplementary data
Journal Articles

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

Kristin K. Zorn, Tomas Bonome, Lisa Gangi, Gadisetti V.R. Chandramouli, Christopher S. Awtrey, Ginger J. Gardner, J. Carl Barrett, Jeff Boyd, Michael J. Birrer
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6422–6430.
https://doi.org/10.1158/1078-0432.CCR-05-0508
Published: 15 September 2005
View article titled, Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer
Open the PDF for Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer in another window
Includes: Supplementary data